The National Institute on Drug Abuse has given Nabi Biopharmaceuticals a $10 million loan to help fund the company's first pivotal clinical trial of NicVAX, a smoking cessation vaccine. It's the largest grant the NIDA has ever handed out, and the third Nabi has received. The company was granted funding during NicVAX's preclinical development and and additional $4.1 million for Phase II testing. And the FDA has given the vaccine fast-track status. Report